New Delhi, Oct. 30 -- Eli Lilly on Thursday raised forecasts for its full-year profit and revenue after the surging popularity of its weight-loss and diabetes drugs, Zepbound and Mounjaro, saw the drugmaker easily surpass third quarter earnings expectations.

Shares of Eli Lilly, currently the world's largest healthcare firm by market capitalisation, soared by 7 per cent in pre-market trading.

Lilly now predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its previous guidance of $21.75 to $23.00 per share.

Investors had been keenly anticipating the drugmaker's latest results, given the exceptionally high expectations for its GLP-1 portfolio and mounting concerns over potential US ...